Distinct antigenic features of linear epitopes at the N-terminus and C-terminus of 65 kDa glutamic acid decarboxylase (GAD65): implications for autoantigen modification during pathogenesis
Open Access
- 19 September 2002
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 130 (1) , 131-139
- https://doi.org/10.1046/j.1365-2249.2002.01960.x
Abstract
Autoantibodies to 65 kDa glutamic acid decarboxylase (GAD65) are produced in many patients with autoimmune polyendocrine syndrome type II (APS‐II) or stiff‐man syndrome (SMS) and are heterogeneous in their epitope specificities, recognizing both conformational and linear determinants. Major linear epitopes of GAD, which are recognized by autoantibodies in a minority of these patients, occur in the N‐terminal and C‐terminal regions. We have investigated antibody recognition of the N‐ and C‐termini of GAD65 in relation to their structural features as an approach to understanding what modifications to the native GAD structure may occur that facilitate the generation of antibodies specific to linear epitopes in these regions during the autoimmune pathogenesis. A monoclonal antibody specific to the N‐terminus of GAD65 bound both native and denatured GAD in ELISA, whereas monoclonal and polyclonal antibodies specific to the C‐terminus of GAD bound only denatured GAD. These antibodies were epitope mapped using random peptide phage‐display libraries and the epitopes related to a previously proposed structural model of GAD65. This has led us to propose that the α‐helical secondary structure of the C‐terminus of GAD65 must be denatured to generate linear epitopes. In contrast, the N‐terminus is both surface exposed and linear in the native structure, but may be masked by membrane interactions, which must be broken to facilitate recognition by B cells.Keywords
This publication has 36 references indexed in Scilit:
- High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylaseJournal of Molecular Biology, 1999
- A Monoclonal Antibody-Based Characterization of Autoantibodies against Glutamic Acid Decarboxylase in Adults with Latent Autoimmune DiabetesAutoimmunity, 1998
- Diagnostic sensitivity of immunodominant epitopes of glutamic acid decarboxylase (GAD65) autoantibodies in childhood IDDMDiabetologia, 1996
- Glutamate Decarboxylase (GAD) is not Detectable on the Surface of Rat Islet Cells Examined by Cytofluorometry and Complement-Dependent Antibody-Mediated Cytotoxicity of Monoclonal GAD AntibodiesHormone and Metabolic Research, 1996
- Brain-reactive autoantibodies in BB/d rats do not recognize glutamic acid decarboxylaseClinical and Experimental Immunology, 1995
- Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus.The Journal of Experimental Medicine, 1994
- Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome.The Journal of Experimental Medicine, 1993
- Characterization of a linear epitope within the human pancreatic 64‐kDa glutamic acid decarboxylase and its autoimmune recognition by sera from insulin‐dependent diabetes mellitus patientsEuropean Journal of Biochemistry, 1993
- Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylaseNature, 1990
- Autoantibodies to Glutamic Acid Decarboxylase in a Patient with Stiff-Man Syndrome, Epilepsy, and Type I Diabetes MellitusNew England Journal of Medicine, 1988